Inion Oyj - Company Announcement

Inion Receives CE Mark Regulatory Clearance for Extended Indications for Inion Hexalon™ Implant

Inion Receives CE Mark Regulatory Clearance for Extended Indications for     
                                     Inion                                      
                                Hexalon™ Implant                                


Tampere, Finland and Guildford, UK. 11 September 2007…Inion [LSE: IIN.L], a     
company focused on the development of novel biodegradable medical implants, has 
received CE Mark* from the British Standards Institution (BSI) for its Inion    
Hexalon™ biodegradable screw for an extended range of clinical procedures       
including soft tissue fixation to bone in surgeries for foot, ankle, hand and   
wrist. This product received equivalent 510(k) regulatory clearance for         
marketing in the USA in August 2007.                                            

The Inion HexalonTM biodegradable screw is the world's first coloured           
biodegradable screw for the surgical fixation of soft tissue (including ligament
and tendon) to bone. It was originally developed and launched for the repair of 
injuries to the anterior and posterior cruciate ligament in the knee where it   
allows clear visibility during arthroscopic insertion (keyhole surgery).        

In addition to knee surgeries, Inion Hexalon™ has now received both CE Mark and 
510(k) clearance for use in surgeries of the shoulder, elbow, ankle, foot, hand 
and wrist, thereby greatly extending the range of trauma injuries it can be used
to treat.                                                                       

Chris Lee, Inion's CEO, said: “Receiving US and European regulatory clearance   
for the extended use of Inion Hexalon™ means that we are now able to offer a    
full range of screw sizes appropriate to the particular surgery in these        
applications, and custom instruments for conducting the procedure, across two of
our focus segments - foot and ankle and upper extremity. The extended range     
means that more patients and surgeons will be able to benefit from the product's
key benefits: its unique enhanced visibility during surgical insertion, its     
strength and its biodegradable properties.”                                     


*CE Mark is issued by a number of accredited bodies to medical device           
manufacturers prior to commercial distribution in the European Union.           
		                                                                              
                                                             -Ends-             
For further information, please contact:                                        
--------------------------------------------------------------------------------
| Inion Oy                                      | Tel: +44 (0)1483 685390      |
| Chris Lee, Chief Executive                    |                              |
| Officer                                       |                              |
| Julien Cotta, Chief Financial Officer         |                              |
--------------------------------------------------------------------------------
| Citigate Dewe Rogerson                        | Tel: +44 (0)207 638 9571     |
| Mark Swallow / David                          |                              |
| Dible / Helena Galilee                        |                              |
--------------------------------------------------------------------------------

About Inion (www.inion.com)                                                     
Inion Oy is a medical devices company focused on the development and successful 
commercialisation of innovative biodegradable and bioactive implants in key     
target markets. The Company's target segments are Spine and Specialty           
Orthopaedics.                                                                   

Inion's core expertise and technology lies in the design and manufacture of     
innovative biodegradable plates, screws, pins and membranes, which are used to  
enhance the healing of bone or soft tissue injuries to the skeleton, such as    
those caused by trauma or by reconstructive surgery. Inion implants are made    
from its proprietary Inion Optima™ family of biomaterials, with properties      
tailored for specific surgical applications, in terms of strength, flexibility  
and rate of degradation                                                         
                                                                                
Inion is also focused on developing proprietary new bioactive and               
biodegradable biomaterials that promote bone healing and accelerate patient     
rehabilitation.                                                                 

Inion was incorporated in early 2000 and listed on the Official List of the UK  
Listing Authority in December 2004. The Company has an office and an R&D        
facility in the UK and head office, R&D and production facilities in Tampere,   
Finland.                                                                        

This announcement includes "forward-looking statements" which include all       
statements other than statements of historical facts, including, without        
limitation, those regarding the Group's financial position, business strategy,  
plans and objectives of management for future operations (including development 
plans and objectives relating to the Group's products), and any statements      
preceded by, followed by or that include forward-looking terminology such as the
words "targets", "believes", "estimates", "expects", "aims", "intends", "will", 
"can", "may", "anticipates", "would", "should", "could" or similar expressions  
or the negative thereof. Such forward-looking statements involve known and      
unknown risks, uncertainties and other important factors beyond the Group's     
control that could cause the actual results, performance or achievements of the 
Group to be materially different from future results, performance or            
achievements expressed or implied by such forward-looking statements. Such      
forward-looking statements are based on numerous assumptions regarding the      
Group's present and future business strategies and the environment in which the 
Group will operate in the future. Among the important factors that could cause  
the Group's actual results, performance or achievements to differ materially    
from those in forward-looking statements include those relating to Inion's      
funding requirements, regulatory approvals, reliance on third parties,          
intellectual property, key personnel and other factors. These forward-looking   
statements speak only as at the date of this announcement. The Group expressly  
disclaims any obligation or undertaking to disseminate any updates or revisions 
to any forward-looking statements contained in this announcement to reflect any 
change in the Group's expectations with regard thereto or any change in events, 
conditions or circumstances on which any such statements are based. As a result 
of these factors, prospective investors are cautioned not to rely on any        
forward-looking statement.